Nuvalent treatment of certain non-small cell lung cancer granted orphan status

Nuvalent’s treatment of ROS1-positive, LTK-positive, ALK-positive, and NTRK fusion-positive non-small cell lung cancer was granted orphan status by the FDA, according to a post the agency’s website. Reference Link